<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03791801</url>
  </required_header>
  <id_info>
    <org_study_id>2019-4576</org_study_id>
    <nct_id>NCT03791801</nct_id>
  </id_info>
  <brief_title>The Use of Sugammadex in the Critically Ill</brief_title>
  <official_title>Recovery From Optimal Neuromuscular Blockade in the Critically Ill: Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Moderate and Deep neuromuscular blockade (rocuronium administered to a train of four count 0&#xD;
      and post-tetanic count of 1-2) in critically ill patients needing intubation or procedures&#xD;
      can be reversed immediately and effectively by sugammadex avoiding unnecessary paralysis in&#xD;
      an already weakened population&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Critically ill is a special population needing immediate and aggressive treatments and&#xD;
      interventions. Neuromuscular blockade is frequently used to secure an airway, optimize&#xD;
      ventilation/oxygenation in ARDS, aid in maintaining hypothermia in patients post-cardiac&#xD;
      arrest. Muscle relaxants can also contribute to neuromuscular weakness in the critically ill&#xD;
      which can be a devastating condition. Appropriate depth of neuromuscular blockade is&#xD;
      important but unnecessary paralysis need to be avoided. Rocuronium is one of the most popular&#xD;
      neuromuscular blockade agents used in the critically ill (1). Sugammadex is a modified&#xD;
      γ-cyclodextrin that reverses the effect of the steroidal nondepolarizing neuromuscular&#xD;
      blocking agents rocuronium and vecuronium (2). Sugammadex results in rapid, predictable&#xD;
      recovery from moderate and deep neuromuscular blockade. Sugammadex has been mostly studied&#xD;
      and used in the surgical population but its use outside the operating room is still very&#xD;
      relevant. The investigators set up to evaluate the potential benefit that may result from the&#xD;
      reversal of NMB with sugammadex compared to neostigmine.&#xD;
&#xD;
      Objectives&#xD;
&#xD;
      In critically ill patients undergoing intubation receiving appropriate depth of NMB (moderate&#xD;
      and deep blockade) the investigators will assess:&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      1. To determine if choice of reversal agent affects time from intubation to return of a train&#xD;
      of four (TOF) count of 1, and, separately, to return of a TOF ratio &gt;0.9&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        1. To document the ability of 1.0 mg/kg rocuronium (maximum 100 mg) to achieve satisfactory&#xD;
           intubation conditions in the ICU, based on measurement of the number of intubation&#xD;
           attempts and intubation grades in the entire cohort&#xD;
&#xD;
        2. To document General adverse effects: Hemodynamic instability, need for vasopressors etc&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>RCT</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Train of four ratio &gt;0.9</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>time from intubation to return of a train of four (TOF) count of 1, and, separately, to return of a TOF ratio &gt;0.9</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Neostigmine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive rocuronium and neostigmine (5-70microg/kg) + glycopyrrolate (10microg/kg) at train of four 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive rocuronium and sugammadex (4mg/kg) after a successful intubation (ETT is in the trachea and secure).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>the reversal of neuromuscular blockade with sugammadex compared to neostigmine.</description>
    <arm_group_label>Sugammadex</arm_group_label>
    <other_name>Bridion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>the reversal of neuromuscular blockade with sugammadex compared to neostigmine.</description>
    <arm_group_label>Neostigmine</arm_group_label>
    <other_name>Prostigmin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <description>Both groups will receive rocuronium for paralysis during intubation</description>
    <arm_group_label>Neostigmine</arm_group_label>
    <arm_group_label>Sugammadex</arm_group_label>
    <other_name>Zemuron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate</intervention_name>
    <description>The reversal of neuromuscular blockade with sugammadex compared to neostigmine/glycopyrrolate</description>
    <arm_group_label>Neostigmine</arm_group_label>
    <other_name>Robinul</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients requiring intubation in the intensive care unit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients younger than 18 yr, to have known or suspected neuromuscular disease,&#xD;
             allergies to medications to be used during intubation, a (family) history of malignant&#xD;
             hyperthermia or severe renal insufficiency (glomerular filtration rate &lt;30 ml/h) will&#xD;
             not be eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roupen Hatzakorzian, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roupen Hatzakorzian, MD MSc</last_name>
    <phone>514 934 1934</phone>
    <phone_ext>31104</phone_ext>
    <email>roupenhatz@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roupen Hatzakorzian, MD, MSc</last_name>
      <phone>514 934 1934</phone>
      <phone_ext>34880</phone_ext>
      <email>roupenhatz@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Roupen Hatzakorzian, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUHC</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 18, 2018</study_first_submitted>
  <study_first_submitted_qc>December 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2019</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Roupen Hatzakorzian, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>sugammadex</keyword>
  <keyword>rocuronium</keyword>
  <keyword>critically ill</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

